From human genome to global genome - why precision medicine must address genetic diversity By Sumit Jamuar, et al. The publication of the first human genome sequence more than 15 years ago marked the start of a new era in medicine. In the years since then, researchers have greatly expanded… Read More
Automating Automation - How close are we to Artificial Intelligence impact? By Dr Michael A. Tarselli, Dr Yohann Potier and Dr Alan E. Fletcher In terms of consistency, repeatability, known errors and sheer volume, there exists perhaps no better collection of data for computer learning than that emerging from automated… Read More
The Reality of Virtual Pharmaceutical Companies By Dr Stephen Naylor and Dr Kirkwood A. Pritchard Jr We discuss the oxymoronic proposition of a Virtual Pharmaceutical Company (VPC) and the typical adopted business model, as well as provide examples of such companies currently trying to undertake this adventurous task. The vagaries… Read More
Integrated Platform Drug Discovery and Development Companies - Part 2: Comparative analysis By Dr Stephen Naylor and Dr Kirkwood A. Pritchard Jr Spring 2019 Large pharmaceutical companies have struggled to efficiently implement tools, technologies and platforms into their drug discovery and development (DDD) programmes. More recently there have been attempts… Read More
Fostering Multidisciplinary Collaboration in Drug Discovery By Professor Zeynep Erden, et al. Drug discovery teams combine specialists with in-depth knowledge from a variety of scientific disciplines. Such diversity in thought worlds poses a challenging exercise in cross-disciplinary collaboration and project coordination. Based on a longitudinal field study of five projects… Read More
Systems Pharmacology: When multi-targeting is advantageous By Dr Kirkwood A. Pritchard Jr, Dr Dustin P. Martin and Dr Stephen Naylor The safety and efficacy of therapeutic drugs still requires improvement. In part this is due to the promiscuity of individual drugs, which on average can interact with an estimated 6-28… Read More
Integrated Platform Drug Discovery and Development Companies - Part 1 By Dr Urban A. Kiernan and Dr Stephen Naylor Technology was lauded as the saviour of the drug discovery and development (DDD) process during the late 1990s. A myriad of independent companies developed and offered ‘innovative’ tools, technologies and platforms… Read More
The Data Driven Transformation In Drug Discovery Dr Satnam Surae This article, presents a review of the current approaches to data management and application within the drug development and research setting, highlighting major critical challenges and emerging solutions for organisations that are determined to harness big data and machine learning. Read More
Disruptive Approaches To Accelerate Drug Discovery and Development (Part 2) By Dr Anton Fliri, et al. Part 2: Emergent intelligence, a new paradigm for drug discovery. (You can read part 1 of disruptive approaches to accelerate drug discovery and development linked here.) The staggering clinical trial failure rate of experimental… Read More
Astrazeneca R&D - Improving Drug Development Productivity With Better Predictivity By Dr Menelas Pangalos & Steve Rees et al. Changing demands in global healthcare over the past 15 years have led to greater complexity and spiralling costs in drug development. The average price tag of taking a new drug from… Read More
Precision Medicine Drugs - Pleonasm or Reality? Dr Urban Kiernan and Dr Stephen Naylor The complexity and uniqueness of human metabolism and physiology in the past decade has been highlighted and dissected. Arguments have been made to suggest that our lack of understanding about human individuality has led to the… Read More
Artificial Intelligence & Biopharma R&D IT By The PRISME Forum This article discusses issues around artificial intelligence & Biopharma R&D IT, and outlines how AI can be a potentially transformative technology for the biopharmaceutical and healthcare industries. "...R&D productivity remains an ongoing concern. Artificial Intelligence and the accompanying analytics are… Read More
Biologics Drug Discovery - Driving Strategic Improvements With Scientific Informatics By Dr Andrew LeBeau Adoption of a scientific informatics system is essential to the success of every drug discovery organisation. This article discusses how we can drive strategic improvements in biologics drug discovery using scientific informatics. Good decisions can accelerate… Read More
Practicalities of Conducting Replication Studies in Preclinical Cancer Biology By Dr Nicole Perfito, Dr Rachel Tsui & Dr Elizabeth Iorns The first results for the Reproducibility Project: Cancer Biology, offer insights into the time and cost of conducting replication studies in preclinical cancer biology. While many agree that developing a… Read More
The Use of Next-Generation Sequencing in Drug Development By Keith Nangle & Mike Furness This article summarises some of the technical and regulatory challenges posed by next-generation sequencing technologies and the efforts being made to address them. Next-generation sequencing (NGS) has moved from the realm of research into those of… Read More
By Paul Avery & Richard Massey Flow cytometry is a powerful tool for cell quantitation and analysis across a wide range of clinical and research applications. Most commonly used in the fields of immunology and haematology, recent improvements in instrument automation and throughput mean that the technique is now emerging… Read More